Inspira Technologies and Ben-Gurion University Have Developed a Platform Designed to Prevent Blood Clotting in Inspira’s ART System

Inspira Technologies Oxy B.H.N. Ltd. (Nasdaq: IINN, IINNW), a breakthrough respiratory medical technology leader, announced today the completion of a development relating to the potential prevention of blood clotting when used in conjunction with its Augmented Respiration Technology (ART) system. The platform is intended to be integrated into the company’s novel ART system, which is currently in its development phase.

The use of anticoagulants for preventing blood clotting during invasive oxygen therapy is standard procedure, despite these drugs posing a high risk. In some cases, anticoagulant medicines increase a person’s risk of life-threatening bleeding in different locations, such as the brain or gastrointestinal tract.

With the potential new platform, created in collaboration with Ben-Gurion University, the company aims to extend the life of oxidizers and potentially prevent blood clotting through its ART system. The research and development process was led by Prof. Joseph Kost, from the Department of Chemical Engineering (Past Dean of the Faculty of Engineering Sciences) at Ben-Gurion University.

and Prof. Kost have developed and characterized a stable polymeric microbubbles (MBs) platform that releases oxygen on demand. The development process required in-depth research to evaluate the procedures for oxygen engulfment in MBs and observe oxygen release at the required rates. This novel proposed technology will be further developed with the aim to integrate it into the ART system, with the view of making it suitable as a dialysis machine and compatible with other blood oxidation systems.

Prof. Kost describes the platform: “The platform is based on polymeric microbubbles MBs with a gas core, made from a PLGA shell (a biocompatible polymer), synthesized by a modified double emulsion solvent evaporation method”.

Dr. Udi Nussinovitch, MD, Ph.D., Co-Founder and CSO of Inspira, said: “I believe that Inspira is developing groundbreaking technology from a medical device and biotechnological perspective. The joined technologies are intended to use innovative molecular approaches and novel oxygenation methods that have the potential to improve patients’ outcomes.”

Medical Device News Magazine
Our publication is dedicated to bringing our readers the latest medical device news. We are proud to boast that our subscribers include medical specialists, device industry executives, investors, and other allied health professionals, as well as patients who are interested in researching various medical devices. We hope you find value in our easy-to-read publication and its overall purpose and objectives! Medical Device News Magazine is a division of PTM Healthcare Marketing, Inc. Pauline T. Mayer is the managing editor.

More News!

“The completion of the APEX-AV Study represents an important milestone in the catheter-directed therapies CDT space for the treatment of pulmonary embolism. I sincerely thank all the investigators for their commitment and dedication,” said William Brent Keeling, MD, Associate Professor of Surgery, Department of Surgery, at the Emory University School of Medicine, and Immediate Past President, The PERT Consortium™.
The combined expertise of Cordance Medical and the Airan and Williams Labs will see NeuroAccess utilized to deliver a novel application of drug-loaded nanoparticles, providing targeted drug delivery to the brain.
Medixine prepares for 2024 with two key senior hires, VP of Operations in the U.S. and VP of Engineering in Finland. The appointments will enhance support and service to the company’s U.S.-based partners, including leading respiratory homecare provider Lincare and a major medical device manufacturer. In addition, the new hires will enable streamlined design, testing, and deployment of new product features for more patient-centric, cost and time-effective treatment of chronic conditions.
Innovent Biologics and Synaffix: Under the terms of the expanded agreement, Innovent will be responsible for the research, development, manufacturing and commercialization of new ADC candidates. Synaffix is eligible to receive an upfront payment plus potentialmilestone payments and royalties on commercial sales for each licensed target.
Data from clinical studies of STK-001 demonstrated clinical benefit for patients ages 2 to 18 years old, including reductions in seizures and improvements in cognition and behavior that support the potential for disease modificatio. Analysis of 72 patients treated in STK-001 clinical trials suggests that higher STK-001 drug exposure in brain leads to greater seizure reductions. Two-year data from the longest prospective natural history study of Dravet syndrome showed that, on average, patients experienced no meaningful improvement in convulsive seizure frequency and exhibited widening gaps in cognition and behavior despite treatment with the best available anti-seizure medicines.

By using this website you agree to accept Medical Device News Magazine Privacy Policy